COOPERATIVE STUDY OF CANCER CHEMOTHERAPY

癌症化疗的合作研究

• 批准号: 3556088
• 负责人: James A. Neidhart
• 金额: $ 13.35万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 1992-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556088
• 关键词: Hodgkin's disease; adult human (21+); azacitidine; bleomycin; bone marrow transplantation; breast neoplasms; central nervous system neoplasms; cervix neoplasms; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; dosage; doxorubicin; drug adverse effect; drug metabolism; flow cytometry; fluorouracil; hematopoietic stem cells; histiocytic lymphoma; human subject; human therapy evaluation; hybrid cells; lomustine; lung neoplasms; lymphocytic leukemia; lymphoma; lymphosarcoma; melanoma; melphalan; membrane activity; meningioma; metastasis; methotrexate; molecular oncology; multiple myeloma; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer palliative treatment; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; online computer; prednisone; procarbazine; radiation therapy dosage; testis neoplasms; urea; vincristine

Patients who have cancer will be treated with Phase III protocols of the Southwest Oncology Group in an interdisciplinary approach utilizing surgery, radiotherapy, chemotherapy (which includes variable schedules and combinations of drugs, including both investigational agents and already proven and accepted drugs, either alone or in combination with radiotherapy; these forms of therapy would represent the current most effective drug combinations identified by group studies), and immunotherapy. Patients who are unresponsive to the above therapy will be managed with new experimental agents, which have been carefully evaluated for dosage and toxicity, and which show suggestive evidence of anti-tumor effect in specific malignancies. These will represent the Phase II protocol studies of the Southwest Oncology Group. Ancillary studies utilizing patient material being evaluated in the above protocols will be coordinated with research activities of other departments in the areas of pathology, immunology, biochemistry, pharmacology, and anatomy through independent grant support. Specifically, the University of New Mexico flow lab will function as one of the referral institutions performing flow cytometry for the Southwest Oncology Group. UNM will also continue to perform cell surface marker analyses on various Southwest Oncology Group leukemia protocols.

癌症患者将接受 III 期方案治疗 西南肿瘤学组的跨学科方法 利用手术、放疗、化疗（包括 可变的时间表和药物组合，包括两者 研究药物和已经证明和接受的药物， 单独或与放射治疗相结合；这些形式的 疗法将代表目前最有效的药物 团体研究确定的组合）和免疫疗法。 对上述治疗无反应的患者将被 用新的实验药物进行管理，这些药物已 仔细评估剂量和毒性，结果表明 在特定恶性肿瘤中具有抗肿瘤作用的提示性证据。 这些将代表第二阶段的协议研究 西南肿瘤学组。 利用正在评估的患者材料进行辅助研究 上述协议将与研究活动协调 其他科室：病理学、免疫学、 通过独立的生物化学、药理学和解剖学 给予支持。 具体来说，新墨西哥大学流程 实验室将作为转介机构之一，执行 西南肿瘤学组的流式细胞术。 新墨西哥州还将 继续对各种细胞进行表面标记分析 西南肿瘤学组白血病方案。